MedTrace Logo

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

NCT05800340 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-04-05

No results posted yet for this study

Summary

Phase II, single-arm, open-label single center study that assess clinical feasibility and safety of 3 cycles neoadjuvant Toripalimab plus chemotherapy in rare mutations stage IIB-IIIB NSCLC followed by optional adjuvant treatment upon investigators' decisions.

Conditions

  • Non-Small Cell Lung Cancer
  • RET Driver Mutation
  • BRAF V600 Mutation
  • Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation
  • MET Amplification
  • MET Exon 14 Skipping Mutation

Interventions

BIOLOGICAL

Toripalimab

240mg Q3W

DRUG

Nab paclitaxel

135 mg/m2, d1, 8 Q3W

DRUG

Pemetrexed

500mg/m2, d1 Q3W

DRUG

Carboplatin

AUC 5, d1 Q3W

Sponsors & Collaborators

  • Shanghai Junshi Bioscience Co., Ltd.

    collaborator OTHER

  • Guangdong Provincial People's Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-04
Primary Completion
2024-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05800340 on ClinicalTrials.gov